Benzinga | Oct 28, 2021 07:14AM EDT

Bausch Health's Canada Unit Reports Its Dermatology Unit Launched New Topical Prescription Treatment For Acne Vulgaris ARAZLO, Available Across Canada

Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company"), and its dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris (common acne), ARAZLOTM (tazarotene) lotion, 0.045% w/w, for patients 10 years of age and older1 is now available across Canada.

ARAZLO is the first tazarotene 0.045% w/w lotion treatment formulated with PRISMATREXTM technology approved by Health Canada that delivers the benefits of tazarotene in a formulation with known hydrating and moisturizers to effectively treat acne with demonstrated efficacy and tolerability.1

"We are very pleased that ARAZLO is now available for prescription by doctors across Canada as an important new option for them to help treat the approximately 5.6 million Canadians who are impacted by acne,"2 said Ginette Gagn?, Interim President and General Manager, Bausch Health, Canada. "We are proud to be expanding our already large dermatology portfolio to better help meet Canadians' needs."

"The availability of ARAZLO provides an important new addition to how we can help our patients with acne by providing access to treatment by the powerful retinoid tazarotene in a lotion form that will help limit the dryness and irritation that has historically been a barrier to its long-term use by patients," 3 said Dr. Benjamin Barankin, MD, FRCPC, FAAD -- Dermatologist, Toronto, Ontario. "It is a very useful and positive step forward for the treatment of acne."

ARAZLO is a lightweight non-greasy lotion that uses a polymeric emulsification system (PRISMATREX), which maintains the emulsion droplets size distribution stable across time and temperature. This system provides stable emulsions by anchoring its hydrophobic portions and forming an adsorbed gel layer around each oil droplet.1

ARAZLO is the third new dermatology treatment from Bausch Health approved by Health Canada in just over 12 months. The other approvals were for BRYHALI(tm) (halobetasol propionate lotion 0.01% w/w), a high to super-high potency topical corticosteroid indicated for corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis, and DUOBRII(tm) (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) to treat adults with moderate to severe plaque psoriasis.4

All three treatments -- ARAZLO, BRYHALI and DUOBRII -- are manufactured at Bausch Health's Laval, Quebec, facility for Canada and the United States.